{"disease":{"id":"refractory-recurrent-central-nervous-system-lymphoma","name":"refractory recurrent central nervous system lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04906902","title":"Acalabrutinib in CNSL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06827782","title":"Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":42,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03581942","title":"Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}